Adastra Pharmaceuticals Overview
- Year Founded
-
2005
- Status
-
Acquired/Merged
- Employees
-
2
- Latest Deal Type
-
M&A
Adastra Pharmaceuticals General Information
Description
Developer of medicines focused on cancer treatment. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin-dependent kinases equipotently, enabling healthcare professionals to ensure the survival of their patients and increase their quality of life.
Contact Information
Website
www.adastrarx.com(Operating Subsidiary)
Corporate Office
- 2929 Campus Drive
- Suite 230
- San Mateo, CA 94403
- United States
Corporate Office
- 2929 Campus Drive
- Suite 230
- San Mateo, CA 94403
- United States
Adastra Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Merger/Acquisition | 07-Sep-2021 | Completed | Clinical Trials - Phase 1 | |||
| 10. Later Stage VC (Series B) | 25-Jan-2021 | Cancelled | Clinical Trials - Phase 1 | |||
| 9. Later Stage VC (Series B) | 24-Apr-2019 | Completed | Clinical Trials - Phase 1 | |||
| 8. Later Stage VC (Series A) | 15-Nov-2016 | Completed | Pre-Clinical Trials | |||
| 7. Later Stage VC (Series 3) | 01-Sep-2015 | Completed | Pre-Clinical Trials | |||
| 6. Later Stage VC (Series 2) | 03-Sep-2013 | Completed | Pre-Clinical Trials | |||
| 5. Later Stage VC (Series 1) | 08-Aug-2012 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 26-Mar-2010 | Completed | Pre-Clinical Trials | |||
| 3. Later Stage VC (Series 1) | 04-Feb-2010 | $5M | $53M | Completed | Pre-Clinical Trials | |
| 2. Early Stage VC (Series 1) | 15-Mar-2007 | $40M | $48M | Completed | Pre-Clinical Trials |
Adastra Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Series 3 | ||||||||
| Series 2 | 3,199,449 | $0.000100 | $0.32 | $4 | $4 | 1x | $4 | 11.24% |
| Series 1 | 4,374,998 | $0.000100 | 8% | $10 | $10 | 1x | $10 | 15.37% |
Adastra Pharmaceuticals Comparisons
Industry
Financing
Details
Adastra Pharmaceuticals Competitors (19)
One of Adastra Pharmaceuticals’s 19 competitors is Euclises, a Venture Capital-Backed company based in Saint Louis, MO.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Euclises | Venture Capital-Backed | Saint Louis, MO | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Amphivena Therapeutics | Venture Capital-Backed | South San Francisco, CA | ||||
| Altimmune | Corporate Backed or Acquired | Gaithersburg, MD | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
Adastra Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Adastra Pharmaceuticals Patents
Adastra Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| ES-2632548-T3 | Solid state forms of macrocyclic kinase inhibitors | Active | 05-Feb-2010 | ||
| EP-2531197-B1 | Solid state forms of macrocyclic kinase inhibitors | Active | 05-Feb-2010 | ||
| EP-2531197-A1 | Solid state forms of macrocyclic kinase inhibitors | Active | 05-Feb-2010 | ||
| EP-2531197-A4 | Solid state forms of macrocyclic kinase inhibitors | Active | 05-Feb-2010 | ||
| CA-2707424-A1 | Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders | Inactive | 28-Nov-2007 | A61K31/402 |
Adastra Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Adastra Pharmaceuticals Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Domain Associates | Venture Capital | Minority | ||
| Lightstone Ventures | Venture Capital | Minority | ||
| Mitsubishi International | Corporation | Minority | ||
| Morgenthaler Ventures | Venture Capital | Minority | ||
| Multiple Myeloma Research Foundation | Corporation | Minority |
Adastra Pharmaceuticals FAQs
-
When was Adastra Pharmaceuticals founded?
Adastra Pharmaceuticals was founded in 2005.
-
Where is Adastra Pharmaceuticals headquartered?
Adastra Pharmaceuticals is headquartered in San Mateo, CA.
-
What is the size of Adastra Pharmaceuticals?
Adastra Pharmaceuticals has 2 total employees.
-
What industry is Adastra Pharmaceuticals in?
Adastra Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Adastra Pharmaceuticals a private or public company?
Adastra Pharmaceuticals is a Private company.
-
What is Adastra Pharmaceuticals’s current revenue?
The current revenue for Adastra Pharmaceuticals is .
-
How much funding has Adastra Pharmaceuticals raised over time?
Adastra Pharmaceuticals has raised $87.6M.
-
Who are Adastra Pharmaceuticals’s investors?
Domain Associates, Lightstone Ventures, Mitsubishi International, Morgenthaler Ventures, and Multiple Myeloma Research Foundation are 5 of 8 investors who have invested in Adastra Pharmaceuticals.
-
Who are Adastra Pharmaceuticals’s competitors?
Euclises, NexImmune, Amphivena Therapeutics, Altimmune, and Inovio Pharmaceuticals are some of the 19 competitors of Adastra Pharmaceuticals.
-
When was Adastra Pharmaceuticals acquired?
Adastra Pharmaceuticals was acquired on 07-Sep-2021.
-
Who acquired Adastra Pharmaceuticals?
Adastra Pharmaceuticals was acquired by Percans Oncology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
